These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30551501)

  • 1. The applications of anti-CD20 antibodies to treat various B cells disorders.
    Payandeh Z; Bahrami AA; Hoseinpoor R; Mortazavi Y; Rajabibazl M; Rahimpour A; Taromchi AH; Khalil S
    Biomed Pharmacother; 2019 Jan; 109():2415-2426. PubMed ID: 30551501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD20 monoclonal antibodies: beyond B-cells.
    Avivi I; Stroopinsky D; Katz T
    Blood Rev; 2013 Sep; 27(5):217-23. PubMed ID: 23953071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.
    Pers YM; Jorgensen C
    Immunotherapy; 2016 Sep; 8(9):1091-6. PubMed ID: 27485081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic potential of anti-CD20 "what do B-cells do?".
    Eisenberg R; Looney RJ
    Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
    Perosa F; Prete M; Racanelli V; Dammacco F
    J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.
    Castillo J; Milani C; Mendez-Allwood D
    Expert Opin Investig Drugs; 2009 Apr; 18(4):491-500. PubMed ID: 19335277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis].
    Di W; Chang Y; Wu YJ; Wei W
    Sheng Li Ke Xue Jin Zhan; 2011 Jun; 42(3):175-80. PubMed ID: 21932514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for B-cell-targeted therapy in autoimmune disease.
    Edwards JC; Cambridge G
    Rheumatology (Oxford); 2005 Feb; 44(2):151-6. PubMed ID: 15509628
    [No Abstract]   [Full Text] [Related]  

  • 9. B-cell: a logical target for treatment of rheumatoid arthritis.
    Youinou P; Jamin C; Saraux A
    Clin Exp Rheumatol; 2007; 25(2):318-28. PubMed ID: 17543163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.
    Taylor RP; Lindorfer MA
    Curr Opin Immunol; 2008 Aug; 20(4):444-9. PubMed ID: 18585457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [B-cell-targeted therapy in the treatment of autoimmune diseases].
    Roll P; Tony HP
    Z Rheumatol; 2009 May; 68(3):255-9. PubMed ID: 19384549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
    Safdari Y; Ahmadzadeh V; Farajnia S
    Invest New Drugs; 2016 Aug; 34(4):497-512. PubMed ID: 27075017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cells and their targeting in rheumatoid arthritis--current concepts and future perspectives.
    Nakken B; Munthe LA; Konttinen YT; Sandberg AK; Szekanecz Z; Alex P; Szodoray P
    Autoimmun Rev; 2011 Nov; 11(1):28-34. PubMed ID: 21777703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
    Czuczman MS; Gregory SA
    Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 therapy and autoimmune disease: therapeutic opportunities and evolving insights.
    Silverman GJ
    Front Biosci; 2007 Jan; 12():2194-206. PubMed ID: 17127456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CD20 antibody for treatment of rheumatoid arthritis].
    Tanaka Y
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():544-8. PubMed ID: 15799415
    [No Abstract]   [Full Text] [Related]  

  • 17. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CD20 antibody for the treatment of systemic autoimmune diseases].
    Tanaka Y
    Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
    [No Abstract]   [Full Text] [Related]  

  • 19. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis.
    Dörner T; Isenberg D; Jayne D; Wiendl H; Zillikens D; Burmester G;
    Autoimmun Rev; 2009 Dec; 9(2):82-9. PubMed ID: 19716441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
    Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
    Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.